Literature DB >> 8232961

MRI assessments of hippocampal pathology in extratemporal lesional epilepsy.

G D Cascino1, C R Jack, F W Sharbrough, P J Kelly, W R Marsh.   

Abstract

We performed a prospective study in 18 patients to determine the extent of MRI-identified hippocampal pathology in patients with intractable partial epilepsy of extratemporal origin. A mesial temporal signal-intensity alteration or hippocampal formation (HF) atrophy, or both, have been shown to be reliable markers of the temporal lobe of seizure origin in patients with mesial temporal sclerosis. All patients subsequently received surgical ablative therapy between 1988 and 1992. During shortterm follow-up, 14 of the 18 patients experienced a significant reduction in seizure tendency, and 12 patients were rendered seizure-free. Qualitative and quantitative (HF volumetry) assessments of HF pathology were performed retrospectively by a blinded investigator. No hippocampal imaging alteration was present in 17 patients. Left HF atrophy was confirmed in one patient with post-traumatic epilepsy who underwent a successful right frontal lobectomy. Morphometric MRI studies rarely identify hippocampal pathology in patients with extratemporal epilepsy.

Entities:  

Mesh:

Year:  1993        PMID: 8232961     DOI: 10.1212/wnl.43.11.2380

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  2 in total

1.  Validation of ictal single photon emission computed tomography with depth encephalography and epilepsy surgery.

Authors:  Vijay M Thadani; Alan Siegel; Petra Lewis; Adrian M Siegel; Barbara C Jobst; Karen L Gilbert; Terrance M Darcey; David W Roberts; Peter D Williamson
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

2.  Use of anterior temporal lobectomy for epilepsy in a community-based population.

Authors:  Jamie J Van Gompel; Ruth Ottman; Gregory A Worrell; Richard Marsh; Nicholas M Wetjen; Gregory D Cascino; Fredric B Meyer
Journal:  Arch Neurol       Date:  2012-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.